Wedge Capital Management’s Charles River Laboratories CRL Stock Holding History

Wedge Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-9,533	Closed	-$786K	–	567
2016 Q2	$786K	Sell	9,533 -1,623	-15%	-$134K	0.01%	354
2016 Q1	$847K	Sell	11,156 -19	-0.2%	-$1.41K	0.01%	338
2015 Q4	$898K	Buy	11,175 +900	+9%	+$64.9K	0.01%	341
2015 Q3	$653K	Buy	10,275 +1,550	+18%	+$111K	0.01%	395
2015 Q2	$614K	Buy	8,725 +2,125	+32%	+$157K	0.01%	418
2015 Q1	$523K	Buy	6,600 +100	+2%	+$7.38K	0.01%	440
2014 Q4	$414K	Sell	6,500 -900	-12%	-$56.4K	﹤0.01%	467
2014 Q3	$442K	Buy	7,400 +875	+13%	+$50.1K	﹤0.01%	460
2014 Q2	$349K	Buy	6,525 +3,000	+85%	+$165K	﹤0.01%	479
2014 Q1	$213K	Buy	+3,525	New	+$205K	﹤0.01%	483
2013 Q4	–	Sell	-5,000	Closed	-$231K	–	497
2013 Q3	$231K	Sell	5,000 -800	-14%	-$36.7K	﹤0.01%	452
2013 Q2	$238K	Buy	+5,800	New	+$248K	﹤0.01%	450

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wedge Capital Management's CRL Position: Q3 2016 in Review

Wedge Capital Management sold out of Charles River Laboratories (CRL) in Q3 2016, closing a stake of 9,533 shares — an estimated $786K sold.

Wedge Capital Management first reported a position in CRL in Q2 2013 and held it in 12 quarters. The position peaked at $898K in Q4 2015. 284 funds tracked by Wall St. Rank hold CRL as of Q3 2016.

Wedge Capital Management reported no remaining Charles River Laboratories position as of Q3 2016 after selling out during the quarter.
Wedge Capital Management sold 9,533 Charles River Laboratories shares in Q3 2016, an estimated $786K.
Wedge Capital Management first reported a position in Charles River Laboratories in Q2 2013 and held it in 12 quarters.
Wedge Capital Management's Charles River Laboratories position peaked at $898K in Q4 2015.
284 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2016.

Based on Wedge Capital Management's 13F filing for Q3 2016, filed 1 Nov 2016.